Evolution of the Average Target: Insulet Corporation

Evolution of the Target Price: Insulet Corporation

Changes in Analyst Recommendations: Insulet Corporation

474ff.JK9K8qrCXwxLBKi0xxeeqmmfOvwTxP9R-d8Kb-kf1Yo.SOAFk_2mHG0uNdrMiHLk7lHtVMVKrLkCm75FOtpvnrpAgnu346sWS35Pzw~4c3510d51a2e9fbd20798bc15072fcce
08-06 Insulet Valuation Attractive Despite Growth Reset Risk, RBC Says MT
08-06 Jefferies & Co. Adjusts Insulet Price Target to $275 From $360 MT
08-06 Stifel Nicolaus Adjusts Insulet Price Target to $180 From $225 MT
08-06 TD Cowen Adjusts Insulet Price Target to $144 From $294 MT
08-06 Baird Adjusts Insulet Price Target to $175 From $248 MT
08-06 Rothschild & Co Redburn Adjusts Insulet Price Target to $165 From $220 MT
08-06 Bernstein Adjusts Insulet Price Target to $175 From $200 MT
08-06 Raymond James Adjusts Insulet Price Target to $180 From $216 MT
08-06 Benchmark Company Adjusts Insulet Price Target to $185 From $250 MT
08-06 Citigroup Adjusts Insulet Price Target to $150 From $172 MT
08-06 UBS Adjusts Insulet Price Target to $150 From $174, Maintains Neutral Rating MT
08-06 RBC Capital Adjusts Price Target on Insulet to $160 From $245, Maintains Outperform Rating MT
08-06 Leerink Partners Downgrades Insulet to Market Perform From Outperform, Adjusts PT to $145 From $247 MT
08-06 Deutsche Bank Adjusts Insulet Price Target to $180 From $190, Maintains Buy Rating MT
08-06 Truist Downgrades Insulet to Hold From Buy, Adjusts Price Target to $153 From $210 MT
08-06 BTIG Downgrades Insulet to Neutral From Buy MT
08-06 JPMorgan Downgrades Insulet to Neutral From Overweight, Adjusts PT to $152 From $275 MT
08-06 Wells Fargo Downgrades Insulet to Equalweight From Overweight, Adjusts PT to $144 From $255 MT
08-06 Oppenheimer Downgrades Insulet to Market Perform From Outperform MT
08-05 Citigroup Cuts Insulet Price Target to $150 From $172 MT
08-05 Piper Sandler Adjusts Price Target on Insulet to $160 From $210 MT
07-28 UBS Downgrades Insulet to Neutral From Buy, Lowers Price Target to $174 From $400 MT
07-13 RBC Lowers Price Target on Insulet to $245 From $280, Keeps Outperform Rating MT
07-13 Truist Lowers Price Target on Insulet to $210 From $219, Keeps Buy Rating MT
07-10 Stifel Adjusts Price Target on Insulet to $225 From $250 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+20.34%
+9.02%
+10.1%
+14.64%
+16.19%
+6.89%
+6.61%
+35.71%
+14.94%
+19.41%
Average +15.38%
Weighted average by Cap. +12.38%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
142.85USD
Average target price
171.91USD
Spread / Average Target
+20.34%
High Price Target
275.00USD
Spread / Highest target
+92.51%
Low Price Target
144.00USD
Spread / Lowest Target
+0.81%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

JPMorgan Chase
Jefferies & Co.
Stifel Nicolaus
TD Cowen
Baird
Rothschild & Co Redburn
Bernstein
Raymond James
Benchmark Company
Citigroup
UBS
RBC Capital Markets
Leerink Partners
Deutsche Bank Securities
Truist Securities
BTIG
Wells Fargo Securities
Oppenheimer
Piper Sandler
Evercore ISI
Goldman Sachs
Barclays
Canaccord Genuity
Wolfe Research
Morgan Stanley
Redburn Atlantic
Nephron Research
Baptista Research
BofA Securities
SVB Leerink
Berenberg Bank
Cowen
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
142.85USD
Average target price
171.91USD
Spread / Average Target
+20.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PODD Stock
  4. Consensus Insulet Corporation